LOC401357: A Negative Regulator of Nrf2 and A Potential Drug Target
LOC401357: A Negative Regulator of Nrf2 and A Potential Drug Target
LOC401357 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain ( NBD) and a conserved transcription factor binding site (TBP).
LOC401357 functions as a negative regulator of the transcription factor Nrf2, which is involved in the detoxification of xenobiotics and other harmful substances. Nrf2 is a transcription factor that is activated in response to DNA damage or other stressors, and it has been implicated in a wide range of cellular processes, including DNA repair, apoptosis, and inflammation.
Loc401357 is a key regulator of Nrf2 activity, and it is thought to play a role in the detoxification of xenobiotics and other harmful substances.
LOC401357 is also a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a conserved transcription factor binding site (TBP).
LOC401357 functions as a negative regulator of the transcription factor Nrf2, which is involved in the detoxification of xenobiotics and other harmful substances. Nrf2 is a transcription factor that is activated in response to DNA damage or other stressors, and it has been implicated in a wide range of cellular processes, including DNA repair, apoptosis, and inflammation.
Studies have shown that LOC401357 plays a crucial role in the detoxification of xenobiotics and other harmful substances. In addition, LOC401357 has also been shown to play a role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation.
LOC401357 is also a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a conserved transcription factor binding site (TBP).
LOC401357 functions as a negative regulator of the transcription factor Nrf2, which is involved in the detoxification of xenobiotics and other harmful substances. Nrf2 is a transcription factor that is activated in response to DNA damage or other stressors, and it has been implicated in a wide range of cellular processes, including DNA repair, apoptosis, and inflammation.
LOC401357 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain ( NBD) and a conserved transcription factor binding site (TBP).
LOC401357 functions as a negative regulator of the transcription factor Nrf2, which is involved in the detoxification of xenobiotics and other harmful substances. Nrf2 is a transcription factor that is activated in response to DNA damage or other stressors, and it has been implicated in a wide range of cellular processes, including DNA repair, apoptosis, and inflammation.
LOC401357 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins, which are characterized by the presence of a nucleotide-binding oligomerization domain (
Protein Name: Uncharacterized LOC401357
The "LOC401357 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC401357 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC401410 | LOC401478 | LOC401480 | LOC401557 | LOC401589 | LOC401703 | LOC401913 | LOC402221 | LOC403312 | LOC407835 | LOC414300 | LOC439933 | LOC440157 | LOC440300 | LOC440311 | LOC440313 | LOC440700 | LOC440864 | LOC440895 | LOC440910 | LOC440982 | LOC441052 | LOC441081 | LOC441087 | LOC441179 | LOC441228 | LOC441239 | LOC441455 | LOC441666 | LOC441722 | LOC441956 | LOC442028 | LOC442497 | LOC497256 | LOC541473 | LOC550113 | LOC553139 | LOC554206 | LOC574080 | LOC606724 | LOC613266 | LOC642131 | LOC642361 | LOC642422 | LOC642502 | LOC642590 | LOC642677 | LOC642730 | LOC642846 | LOC642947 | LOC643201 | LOC643339 | LOC643406 | LOC643441 | LOC643454 | LOC643763 | LOC643855 | LOC643923 | LOC644006 | LOC644083 | LOC644086 | LOC644189 | LOC644215 | LOC644277 | LOC644525 | LOC644584 | LOC644634 | LOC644656 | LOC644662 | LOC644669 | LOC644893 | LOC644936 | LOC645086 | LOC645181 | LOC645188 | LOC645266 | LOC645468 | LOC645503 | LOC645967 | LOC646044 | LOC646214 | LOC646358 | LOC646471 | LOC646674 | LOC646736 | LOC646762 | LOC646813 | LOC646836 | LOC646853 | LOC646903 | LOC646934 | LOC646970 | LOC647115 | LOC647132 | LOC647481 | LOC649133 | LOC650157 | LOC650226 | LOC651536 | LOC652276
